BioMérieux Acquires Day Zero Diagnostics to Enhance Sequencing Abilities

On June 16, 2025, bioMérieux announced a strategic acquisition of Day Zero Diagnostics, a US-based company specializing in infectious disease diagnostics. This move aims to advance bioMérieux's next-generation sequencing (NGS) capabilities. The acquisition supports the company's commitment to healthcare advancement and antimicrobial stewardship.

Day Zero Diagnostics has pioneered technologies that enable rapid bacterial pathogen identification and antibiotic resistance profiling directly from whole blood samples, significantly reducing diagnostics time from days to hours. This includes NGS workflows and bioinformatics software now part of bioMérieux's assets.

The integration of these solutions enhances bioMérieux's R&D pipeline to meet critical needs in infectious disease diagnostics, such as the management of severe conditions like sepsis. This acquisition, valued at under USD 25 million, bolsters bioMérieux's long-term growth strategy beyond 2028.